for more than 20 years. [1] [2] [3] [4] [5] Early studies in children, using the standard total adult busulphan dose of 16 mg/kg, reported decreased toxicity, increased graft rejection and Busulphan (BU) pharmacokinetic (PK) studies in children undergoing bone marrow transplantation suggest increased neoplastic relapse in children compared to adults. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Subsequent pharmacokinetic studies have conthat individual BU dosing may be necessary to optimise BU systemic exposure. Optimising BU systemic firmed that, at this dose, children achieve significantly lower busulphan systemic exposure as measured by the area exposure may improve outcome and decrease toxicity in BMT. Because of practical limitations in obtaining under the curve (AUC) of busulphan vs time. [12] [13] [14][15][16][17][18][19] [20] Busulphan dosing, based on surface area, in children (busulphan blood from children and for financial reasons, a limited sampling method (LSM) is needed. However, such 600 mg/m 2 ) has been associated with BU AUCs that were similar to adults and with acceptable toxicity, but the wide methods for BU have not been validated in children. In the present study, we individualized oral BU dosing in inter-patient variability in AUCs persists. 14-18 Age, disease, circadian rhythms, food, drugs and pretransplant liver 10 children to target an area under the curve of BU (BU AUC) of 900-1400 M/min based on BU AUC 0-ؕ abnormalities have been identified as causes of variability in busulphan disposition.
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Nine blood samples (2-3 ml heparinised blood) were drawn 
Busulphan assay
a See text: Bulsulphan administration.
Plasma busulphan concentrations were determined using gas chromatography with electron capture detection (GCBusulphan administration ECD) with 1,5-pentanediol dimethanesulfonate as the internal standard (a modification of a previously All patients received a 'test/therapeutic' dose of busulphan (40 mg/m 2 , to the nearest tablet; Burroughs-Wellcome, described method).
23,24
The extraction process was as follows: 250 l of Montreal, Quebec; 2 mg/tablet) prior to their busulphan course. Body surface area was calculated using the formula patient's plasma and 10 l internal standard (25 g/ml) were mixed with 750 l sodium iodide 4 M. The mixture of Haycock et al, 22 based on weight and height. Patients were kept nil per os (NPO) for a minimum of 2 h before was vortexed for 30 s and 400 l hexane was added. The mixture was vortexed again, and incubated for 60 min at and 1 h after administration of the test dose. The test dose was given as crushed tablets in water, via a nasogastric 70°C. The sample was cooled to room temperature and centrifuged. One microliter of the hexane layer was injected tube, as fast as possible or over a maximum of 5 min. Patient 4 received the dose orally. Patient 7 received VPinto a gas chromatograph with an electrochemical detector. The detection limit of the assay was 0.1 mol. Commercial 16/busulphan/cyclophosphamide conditioning. To avoid any as yet unknown interaction between VP-16 and busulplasma was spiked with known concentrations of busulphan (0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 10.0 mol) and processed as phan, the busulphan test dose was performed prior to the VP-16 administration, and the patient received no busulabove, simultaneously with the patient's plasma. The results were analysed by linear regression to obtain an equphan for 48 h after the VP-16 allowing VP-16 to be eliminated from the body (t .␤ = 11.5 h). Most patients received ation for the standard curve. This equation was used to calculate the busulphan concentrations from the patient's the dose at 0600 h but two patients received their dose at 1300 h. All children received phenytoin, during the busulsamples. The interday coefficient of variation for low and high quality assurance samples (n = 44) respectively were phan course for seizure prophylaxis. The modified busul- al 21 (study in adults) and our three-sample method (above).
Pharmacokinetics

Statistical analyses
The area under the curve of busulphan to infinity (AUC)
The limited sampling AUCs were compared to the ninewas calculated using two methods. (1) Manually using the sample Kinfit-derived AUC (regarded as our gold standard) trapezoidal rule until the last data point and estimation of using the Pearson correlation co-efficient 27 and the two the AUC from the last data point to time infinity based on tailed paired t-test.
28
the elimination rate constant (K e ) obtained from the log BU To assess the limited sampling methods, the percentage concentration vs time curve; 25 and (2) computer fitting of difference (% diff) between the 'LSM-derived AUC 0-ϱ the busulphan concentration-time data to a one compart-(limited AUC) and the 'Kinfit-derived AUC 0-ϱ (AUCkinfit) mental model with first order absorption and elimination was calculated for each patient. The difference, whether kinetics, using a nonlinear regression analysis program positive or negative, was used to calculate the mean percent (KINFIT). 26 Results were expressed as m/min. difference (mean % diff) between the limited AUCs and the AUCkinfit.
A post hoc power analysis, for a two-tailed test, was perCalculation of the modified dose formed to determine the power of this study to detect a difference of 10% of the mean percentage difference The adjusted BU dose was calculated as follows (rounded between the AUCkinfit and our three-sample LSM AUC. to the nearest tablet):
AUC 0-ϱ was correlated with trough levels using least square regression analysis.
The intended acceptable target BU AUC range was 900-Clinical monitoring 1400 m/min. Calculations were based on achieving a tarThe patients were monitored for hepatic VOD and mucoget AUC of 1300 m/min. Some patients' doses were calsitis according to previously published criteria. 8 The cliniculated to achieve a lower target, due to concerns of toxcal criteria used for the diagnosis of VOD were the presicity (see Discussion for the rationale of the different ence of two or more of the following occurring within 21 targets used).
days post-transplantation in the absence of other causes of liver disease: bilirubin Ͼ2 mg/dl, unexplained weight gain 5% of baseline weight or presence of ascites, and hepatoDevelopment of the limited sampling method megaly or right upper quadrant tenderness. Complete blood Limited sampling AUCs were calculated using a combicounts were monitored daily with differential counts every nation of the trapezoidal rule (for concentrations to the penalternate day. Bilirubin levels were monitored twice weekly ultimate measured BU concentration, C x , where x is the or as clinically indicated. time at the second to last measured busulphan concentration data point for the particular data set) and logarithmic rule (from the penultimate measured BU concentration to infinResults ity using the formula: C x /K e ). This was done using twosample, three-sample and four-sample time points as shown Pharmacokinetics below. The limited AUCs were compared as described under statistical analysis. The formulae used were as fol-
The data from patient 4 was excluded from analysis lows:
because of vomiting of the BU test dose. The natural logarithm of the measured busulphan concentrations vs time, for the other nine patients, is shown in Figure 1 . Eight of nine (1) Two-sample (1, 6 h): 30C1h + 300C1h/(Ln C1h − patients had an observed t max (time to observed maximal Ln C6h) concentration) at either 60 or 90 min. The busulphan con-(2) Three-sample (1, 1.5, 6 h): 45C1h + 15C1.5h + centrations obtained fitted well to the one compartmental, 270C1.5h/(Ln C1.5h − Ln C6h) first order pharmacokinetic model used.
The computer derived BU AUC 0-ϱ (AUCkinfit), for each patient is shown in Figure 2 shows the linear regression plot of the three-sample AUC vs AUCkinfit in which the correlation (r = 0.976, P = 0.001) was excellent. The limited AUCs derived from the two-sample, three-sample and the various four-sample limited sampling methods outlined in Table 3 were highly significantly correlated with, and were not statistically different from AUCkinfit. However, when the percentage difference between the limited AUC and AUCkinfit was calculated for each individual patient, the range of the percentage difference varied according to the limited sampling method used. The three-sample limited AUC and the four-sample limited AUC using either the BU concentration at 120 min or 180 min resulted in AUCs that most closely approximated the AUCkinfit with a mean absolute percentage difference of 7.5, 7.4 and 7.07% respectively. The range of the percentage differences were also quite similar and close to ±10% of our standard, AUCkinfit. 
Development of the limited sampling method
Busulphan dose adjustment
Six of nine evaluable patients needed dose adjustments. The actual targeted BU AUC and the recommended dose changes are shown in Table 2 . In the six patients whose doses were adjusted, the mean dose change (calculated from the absolute value of the dose change, whether positive or negative) was 26.2% (range −33.3% to +45.3%). The Kinfit-derived AUC is given in Table 2 .
Results of statistical power analysis
The power analysis, for a two-tailed test comparing the means of two related groups and to detect a difference of 10% in the mean percent difference between the means of the AUCkinfit and our three-sample LSM AUC yielded a Z ␤ value of 9.2. This corresponds to a ␤ of Ͻ0.005 (Z ␤0.005 = 2.58). Therefore, this study has a power of Ͼ99% to detect at the 5% significance level a difference in the mean percent difference between our standard AUCkinfit and our three-sample LSM AUC of 10%.
Correlation between AUC 0-ϱ and busulphan trough concentrations (test dose)
The AUCkinfit of the test dose was significantly correlated (r = 0.945, P = 0.0001) with the corresponding trough BU concentration level as shown in Figure 4 .
Toxicity
Six patients had mucositis (two mild and four severe) requiring morphine, two required morphine doses Ͼ50 g/kg/h. (15.5 to 36 mg/kg) compared to our previous standard dose (16 mg/kg).
Comparison of published limited sampling methods Patient outcome
Patient 1 had autologous marrow recovery. The dose for Figure 3 and Table 4 show the results of applying our busulphan concentration time data to the formulae reported by this patient was not adjusted because of possible toxicity. Five patients (two allogeneic and three matched unreVassal et al 16 (study in children) and Schuler et al 21 (study in adults). It also shows the percentage differences of the lated donor) are fully engrafted. The medians (ranges) of the time to the following outcome measures were: reticuloAUCs calculated using these methods to the AUCkinfit. than only three samples. Limited sampling methods may be almost as accurate and overcome these disadvantages. Trough BU levels have not been evaluated.
The coefficient of variation of many tests regarded as being accurate is in the order of ±10%. Therefore, a limited sampling method with an accuracy of ±10% is reasonable.
We compared our LSM AUCs with our AUCkinfit and LSMs from the literature using our data. Our three-sample and four-sample methods resulted in LSM AUCs that were highly significantly correlated and not statistically different from our standard (AUCkinfit). However, our LSM AUCs had a narrower range and a smaller mean percentage difference when compared to the other methods described below.
The LSM AUCs obtained using the method of Vassal et al 16 were highly correlated and not statistically different from our standard. However, the range of differences between the LSM AUCs and the standard was much wider and with a higher mean percentage difference than our three-sample method. The LSM AUCs using both methods of Schuler et al 21 were less well correlated, statistically different from the standard AUCkinfit (P р 0.05), and had a much wider range of differences from the standard. Their methods may not be applicable in children. Also, Schuler's calculations were based on AUC 0-6h at first dose, whereas we calculated AUC 0-ϱ . The AUC 0-6h calculated using our cyte count of 10 × 10 9 /l: 20 days (range: 14-56); absolute granulocyte count of Ͼ0.5 × 10 9 /l: 18 days (range: 10-52); busulphan concentration-time data (data not shown), was still significantly different from that calculated by the and platelet count of Ͼ50 × 10 9 /l: 29 days (range: 21-68). Three of four patients (3, 6 and 9) with autotransplants for
Schuler et al 21 method. Hassan et al 30 recently suggested a three-sample LSM AML failed to achieve a platelet count of 50 × 10 9 /l by 2.5 to 9 months post-transplant. Of these, patients 6 and 9 for children at 1 h, 3 h and 6 h. Our data applied to this linear regression equation resulted in a mean BU AUC of require ongoing platelet and red cell transfusions.
1097 m/min which is not significantly different (P = 0.54) from our AUCkinfit. The mean percentage difference was 10.9%, which is higher than that of our three-sample Discussion method (7.5%) and that of Vassal et al 16 (9.58%). The range of differences between the LSM AUCs and the stanBusulphan pharmacokinetics in children are significantly different from those in adults. There is wide inter-patient dard was −20.3% to 12.4%. The differences in the AUCs obtained may be due to variations in the method of drug variability of busulphan kinetics in children. Recent evidence supports the hypothesis that toxicity and outcome in administration, and differences in the times to maximal concentrations among the studies. children may depend on the BU AUC achieved. 29 Many authors have therefore recommended busulphan therapeutic It must be noted that Vassal et al 16 and Hassan et al 30 use different units of measurement (concentration, ng/ml; drug monitoring and individualised busulphan dose adjustment to optimise BU systemic exposure while minimising AUC, ng/h/ml). The regression equations reported by these groups are based on these units and therefore one cannot regimen-related toxicity.
Our study shows clinically significant busulphan dose apply concentrations in m directly to these equations. To obtain an accurate AUC from these equations a correction adjustments (−33.3% to +45.3%) are necessary in a large proportion of children (Ͼ66%) despite surface area based factor (×60) must be used to obtain an AUC in m/min. This is based on the following conversions: 1 m = 246.3 dosing. This finding suggests that individualised dose adjustment is necessary in children receiving high dose busng/ml and 1 m/min = 4.1 ng/h/ml. Our results suggest that either a three-sample or a fourulphan therapy prior to bone marrow transplantation. Schuler et al 21 recently suggested that busulphan monitorsample method can be used. Both methods yield similar results. There is no significant advantage to using the fouring is not warranted except for research purposes. Their study population included only two patients 18 years of sample method. There will be less blood sampling and other associated costs by using the three-sample method. age or younger. This conclusion may be appropriate only in adults.
Therefore, we now use our three-sample limited sampling method to test patients BU AUC before dose adjustment, The standard nine to 12 sample pharmacokinetic study used to derive BU AUC, is the most accurate. Disadvanand after dose adjustment to assess the effectiveness of dose adjustment. It may also be used to carry out further dose tages of performing a full pharmacokinetic study include the following: more blood sampling is required; it is more adjustments. The AUCkinfit was highly correlated with the trough time-consuming for staff and it is much more expensive busulphan concentrations achieved. Further study is neces-(total BU doses ranging from 15.5 to 36 mg/kg). This includes those patients whose target AUC was near 1300 sary to test whether trough busulphan levels are a reliable predictor of BU AUC. Trough levels could become very m/min. Previously, our standard busulphan doses were 1 mg/kg/dose for patients Ͼ3 years old and 1.25 mg/kg/dose useful for monitoring BU systemic exposure and perhaps for further dose adjustment during the course of busulfor children Ͻ3 years old. Our patients now receive busulphan to target an AUC of 1300 m/min. phan therapy.
Eight of nine of our patients had observed times to maxiYeager et al 18 reported VOD in one of seven patients and Slattery et al 29 reported VOD in five of 28 patients mal concentration (t max ) at either 60 or 90 min. Previously reported t max values varied widely ranging from 30 min to (children Ͻ18 years of age). These patients received fixed dose busulphan, 27.7 mg/kg and 14 to 17 mg/kg total dose, 180 min 30 and as long as 255 min. 12 It is possible that the formulation of the busulphan tablets and their dissolution respectively. Recently, Slattery et al 29 reported an increased risk of grade 3-4 toxicity (including VOD) in adults and characteristics may be a factor. Ehninger et al 31 recently reported studies in a canine model using a solution of busulchildren receiving an average steady state busulphan concentration Ͼ900 ng/ml (equivalent to BU AUC of approxiphan in dimethyl sulphoxide (DMSO). They suggested that the problems of physico-chemical dispersion of the tablets mately 1320 m/min). Data were also presented on two children which suggests VOD may develop at BU levels is a source of inter-patient and intra-patient variability. The t max after oral dosing ranged from 30 to 90 min and AUCs much less than 900 ng/ml. Cyclophosphamide, etoposide, total body irradiation and other drugs may cause VOD indeachieved were Ͻ10% different from that obtained by intravenous administration of the same dose of this solution.
pendently or contribute to its development. Previous liver disease or previous liver irradiation may also be factors. Our findings of a fairly consistent t max in our patients, after administration of crushed tablets in water, may provide
Further study taking these factors into account is necessary to determine whether targeting BU AUC will result in human data to support this theory. DMSO may not be necessary. Perhaps, busulphan packaged in powdered form decreasing VOD in children.
The incidence of mucositis in this study (67%) is compain a gel capsule may help to reduce this variability in busulphan absorption but any variability in gel solubility may rable to that reported in previous studies (57%, 18 64% 30 ). The other toxicities reported are more likely related to complicate this approach.
Hassan et al 32 reported the variability of busulphan irradiation and cyclophosphamide. Patients with mucopolysaccharide storage disease have bioavailability (bioavailability, F = 0.22 to 1.20) in children. This may be a major factor in the variability in problems with graft rejection and autologous marrow recovery, especially in unrelated transplants. 33 Patient 1 observed BU AUC.
The optimal BU AUC exposure required for efficacy in may be representative of this. He had Hurler's syndrome and received an unrelated donor transplant. He did not have children is not known and may be different for different diseases. We have chosen to target an AUC (1300 m/min) T cell depletion or any other predisposing factors to graft rejection. This patient was our first study patient. We would between the mean adult level (1268 m/min
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) and the level reportedly associated with an increased risk of serious toxhave targeted a higher AUC if we had previous experience using the much larger doses that would have been required. icity. An upper limit of AUC of 1400 m/min was used as a margin of safety to reduce the risk of VOD assuming a Subsequently, Slattery et al 29 reported that higher levels of busulphan exposure were associated with better ±10% laboratory error/variability. For patients in whom there were concerns about the high busulphan dose, the engraftment rates in unrelated donor transplants. Perhaps the risk of graft failure in storage diseases with unrelated dose was calculated to target an AUC of 1100 m/min, based on data where the mean AUC achieved in children donor transplants requires maximal target BU AUC. We have changed our protocol in patients with storage diseases with a dose of 40 mg/m 2 was 1105 m/min. 18 Failing this, the minimum AUC targeted was 900 m/min, the lowest to busulphan, cyclophosphamide 60 mg/kg × two doses and total body irradiation 300 cGy × one dose. We do not value of our 'acceptable range'. We have partly validated this therapeutic window in children, but more clinical studuse antithymocyte globulin or T cell depletion with this protocol. ies are needed. There is evidence that higher busulphan exposure yields better results in unrelated transplants. 29 As In those patients who engrafted, the time to engraftment is comparable to other published data. 18 We think that the further data are acquired, it is likely that analysis will suggest that different levels of busulphan exposure may be engraftment problems in three patients were related to aggressive chemotherapy of their acute nonlymphocytic efficacious for different diseases. By adjusting doses based on measured AUC, the inter-patient variability in BU AUC leukemia prior to marrow harvest and probably not related to BU-CY conditioning. Long-term outcome data, achieved will be markedly reduced and the toxicity data from this approach will be helpful in guiding therapy in especially relapse in malignancy, is not available. Further follow-up is necessary. the future.
An increased risk of VOD was reported in patients Our data strongly suggest that individualised busulphan dosing is necessary in most children to achieve maximal achieving BU AUC Ͼ1500 m/min. 19 We thought it prudent to keep the BU exposure level below 1400 m/min targeted systemic exposure. Toxicity and engraftment rates are acceptable within the targeted range of busulphan AUC. for an extra margin of safety. This was the reason for decreasing doses in three of six of our patients who had
The proposed three-sample limited sampling method gives an accurate estimate of busulphan AUC with improved dose adjustment. No patient in this series developed VOD with the current doses ranging from 0.91 to 2.3 mg/kg/dose results compared to previous reported methods. This 
